February 13, 2024 07:26 AM ESTUpdated 09:20 AM

G1 Therapeutics' stock sinks nearly 40% on PhIII readout delay

Katherine Lewin

News Reporter

G1 Therapeutics announced that it will be continuing its Phase III breast cancer trial for its drug Cosela following an interim analysis, pushing back a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

G1 Therapeutics' stock sinks nearly 40% on PhIII readout delay

Katherine Lewin

News Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Key GOP senator is ‘struggling’ with Kennedy nomination over vaccine answers

Roche aims for derisked deals and ruthless portfolio cuts in 2025

Blackstone secures $1.6B so far for new life sciences fund targeted at $5B+

Takeda scraps programs as it raises full-year guidance

Sanofi is in the market for M&A, thanks to ‘strong’ balance sheet

Why the premier recruitment agency in the world is giving up recruiting, and sponsors should, too

G1 Ther­a­peu­tic­s' stock sinks near­ly 40% on PhI­II read­out de­lay

News Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

G1 Therapeutics' stock sinks nearly 40% on PhIII readout delay